Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.

Schnell O, Albrecht V, Pfirrmann D, Eigenbrod S, Krebs B, Romagna A, Siller S, Giese A, Tonn JC, Schichor C.

Med Oncol. 2018 Jun 7;35(7):103. doi: 10.1007/s12032-018-1162-z.

PMID:
29882028
2.

Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice.

Eigenbrod S, Frick P, Bertsch U, Mitteregger-Kretzschmar G, Mielke J, Maringer M, Piening N, Hepp A, Daude N, Windl O, Levin J, Giese A, Sakthivelu V, Tatzelt J, Kretzschmar H, Westaway D.

PLoS One. 2017 Dec 8;12(12):e0188989. doi: 10.1371/journal.pone.0188989. eCollection 2017.

3.

Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas.

Thorsteinsdottir J, Stangl S, Fu P, Guo K, Albrecht V, Eigenbrod S, Erl J, Gehrmann M, Tonn JC, Multhoff G, Schichor C.

J Neurooncol. 2017 Dec;135(3):443-452. doi: 10.1007/s11060-017-2600-z. Epub 2017 Aug 28.

PMID:
28849427
4.

Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.

Thon N, Thorsteinsdottir J, Eigenbrod S, Schüller U, Lutz J, Kreth S, Belka C, Tonn JC, Niyazi M, Kreth FW.

J Neurol. 2017 Feb;264(2):350-358. doi: 10.1007/s00415-016-8355-1. Epub 2016 Dec 5.

PMID:
27921166
5.

Quantifying prion disease penetrance using large population control cohorts.

Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, McLean CY, Tung JY, Yu LP, Gambetti P, Blevins J, Zhang S, Cohen Y, Chen W, Yamada M, Hamaguchi T, Sanjo N, Mizusawa H, Nakamura Y, Kitamoto T, Collins SJ, Boyd A, Will RG, Knight R, Ponto C, Zerr I, Kraus TF, Eigenbrod S, Giese A, Calero M, de Pedro-Cuesta J, Haïk S, Laplanche JL, Bouaziz-Amar E, Brandel JP, Capellari S, Parchi P, Poleggi A, Ladogana A, O'Donnell-Luria AH, Karczewski KJ, Marshall JL, Boehnke M, Laakso M, Mohlke KL, Kähler A, Chambert K, McCarroll S, Sullivan PF, Hultman CM, Purcell SM, Sklar P, van der Lee SJ, Rozemuller A, Jansen C, Hofman A, Kraaij R, van Rooij JG, Ikram MA, Uitterlinden AG, van Duijn CM; Exome Aggregation Consortium (ExAC), Daly MJ, MacArthur DG.

Sci Transl Med. 2016 Jan 20;8(322):322ra9. doi: 10.1126/scitranslmed.aad5169.

6.

Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.

Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Pöpperl G, Kreth FW, la Fougere C, Weller M, Tonn JC; German Glioma Network.

Neurology. 2015 Feb 17;84(7):710-9. doi: 10.1212/WNL.0000000000001262. Epub 2015 Jan 21.

7.

Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.

Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn JC, Bartenstein P, Kreth FW, la Fougère C.

J Nucl Med. 2015 Jan;56(1):9-15. doi: 10.2967/jnumed.114.144675.

8.

Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses.

Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, Lutz J, Egensperger R, Giese A, Herms J, Weller M, Kretzschmar H, Tonn JC, la Fougère C, Kreth FW.

Int J Cancer. 2015 May 1;136(9):2132-45. doi: 10.1002/ijc.29259. Epub 2014 Nov 3.

9.

Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.

Eigenbrod S, Trabold R, Brucker D, Erös C, Egensperger R, La Fougere C, Göbel W, Rühm A, Kretzschmar HA, Tonn JC, Herms J, Giese A, Kreth FW.

Acta Neurochir (Wien). 2014 Aug;156(8):1427-40. doi: 10.1007/s00701-014-2073-1. Epub 2014 May 3.

PMID:
24792966
10.

Male sex as a risk factor for the clinical course of skull base chordomas.

Rachinger W, Eigenbrod S, Dützmann S, Simon M, Feigl GC, Kremenevskaja N, Kretzschmar H, Zausinger S, Kreth FW, Thon N, Tonn JC.

J Neurosurg. 2014 Jun;120(6):1313-20. doi: 10.3171/2013.11.JNS131137. Epub 2014 Jan 3.

PMID:
24405075
11.

Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Drexler M, Bartenstein P, Schnell O, Tonn JC, Thon N, Kreth FW, la Fougère C.

J Nucl Med. 2014 Feb;55(2):198-203. doi: 10.2967/jnumed.113.122333. Epub 2013 Dec 30.

12.

[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma.

Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, Bartenstein P, Belka C, Kreth FW, la Fougère C.

Mol Imaging. 2013 May;12(3):137-47.

PMID:
23490440
13.

Report about four novel mutations in the prion protein gene.

Schelzke G, Stoeck K, Eigenbrod S, Grasbon-Frodl E, Raddatz LM, Ponto C, Kretzschmar HA, Zerr I.

Dement Geriatr Cogn Disord. 2013;35(3-4):229-37. doi: 10.1159/000345991. Epub 2013 Mar 5.

PMID:
23467330
14.

Atypical parkinsonism due to a D202N Gerstmann-Sträussler-Scheinker prion protein mutation: first in vivo diagnosed case.

Plate A, Benninghoff J, Jansen GH, Wlasich E, Eigenbrod S, Drzezga A, Jansen NL, Kretzschmar HA, Bötzel K, Rujescu D, Danek A.

Mov Disord. 2013 Feb;28(2):241-4. doi: 10.1002/mds.25188.

PMID:
23436635
15.

Optical needle endoscope for safe and precise stereotactically guided biopsy sampling in neurosurgery.

Göbel W, Brucker D, Kienast Y, Johansson A, Kniebühler G, Rühm A, Eigenbrod S, Fischer S, Goetz M, Kreth FW, Ehrhardt A, Stepp H, Irion KM, Herms J.

Opt Express. 2012 Nov 19;20(24):26117-26. doi: 10.1364/OE.20.026117.

PMID:
23187467
16.

Isolation and characterization of bone marrow-derived progenitor cells from malignant gliomas.

Guo KT, Juerchott K, Fu P, Selbig J, Eigenbrod S, Tonn JC, Schichor C.

Anticancer Res. 2012 Nov;32(11):4971-82.

PMID:
23155267
17.

Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.

Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, Pöpperl G, Kretzschmar HA, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougère C, Thon N.

Neuro Oncol. 2012 Dec;14(12):1473-80. doi: 10.1093/neuonc/nos259. Epub 2012 Oct 22.

18.

Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET.

Niyazi M, Jansen N, Ganswindt U, Schwarz SB, Geisler J, Schnell O, Büsing K, Eigenbrod S, la Fougère C, Belka C.

J Neurooncol. 2012 Dec;110(3):389-95. doi: 10.1007/s11060-012-0980-7. Epub 2012 Oct 4.

PMID:
23054562
19.

Extramedullary multiple myeloma presenting as a pituitary mass lesion.

Dimopoulou C, Ormanns S, Eigenbrod S, Müller-Lisse U, Emmerich B, Reincke M.

Exp Clin Endocrinol Diabetes. 2012 Sep;120(8):501-4. doi: 10.1055/s-0032-1321810. Epub 2012 Jul 31.

PMID:
22851185
20.

Intramedullary pilomyxoid astrocytoma with intracerebral metastasis exhibiting oligoden-droglioma-like features.

Eigenbrod S, Thon N, Jansen N, Janssen H, Mielke J, Ruiter M, la Fougère C, Peraud A, Egensperger R, Kretzschmar H.

Rare Tumors. 2012 Apr 12;4(2):e30. doi: 10.4081/rt.2012.e30. Epub 2012 May 31.

21.

FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status.

Niyazi M, Schnell O, Suchorska B, Schwarz SB, Ganswindt U, Geisler J, Bartenstein P, Kreth FW, Tonn JC, Eigenbrod S, Belka C, la Fougère C.

Radiother Oncol. 2012 Jul;104(1):78-82. doi: 10.1016/j.radonc.2012.04.022. Epub 2012 Jun 5.

PMID:
22673727
22.

MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougère C.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1021-9. doi: 10.1007/s00259-012-2109-9. Epub 2012 Apr 11.

PMID:
22491781
23.

ALDH1A1 is a marker of astrocytic differentiation during brain development and correlates with better survival in glioblastoma patients.

Adam SA, Schnell O, Pöschl J, Eigenbrod S, Kretzschmar HA, Tonn JC, Schüller U.

Brain Pathol. 2012 Nov;22(6):788-97. doi: 10.1111/j.1750-3639.2012.00592.x. Epub 2012 Apr 19.

PMID:
22417385
24.

Magnetic resonance imaging in E200K and V210I mutations of the prion protein gene.

Breithaupt M, Romero C, Kallenberg K, Begue C, Sanchez-Juan P, Eigenbrod S, Kretzschmar H, Schelzke G, Meichtry E, Taratuto A, Zerr I.

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):87-90. doi: 10.1097/WAD.0b013e31824d578a.

PMID:
22407223
25.

Krüppel-like factor 8 (KLF8) is expressed in gliomas of different WHO grades and is essential for tumor cell proliferation.

Schnell O, Romagna A, Jaehnert I, Albrecht V, Eigenbrod S, Juerchott K, Kretzschmar H, Tonn JC, Schichor C.

PLoS One. 2012;7(1):e30429. doi: 10.1371/journal.pone.0030429. Epub 2012 Jan 19.

26.

Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors.

Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Münzel M, Müller M, Pfaffeneder T, Hackner B, Feiden W, Schüller U, Carell T, Kretzschmar HA.

Int J Cancer. 2012 Oct 1;131(7):1577-90. doi: 10.1002/ijc.27429. Epub 2012 Mar 2.

27.

MiRNA expression patterns predict survival in glioblastoma.

Niyazi M, Zehentmayr F, Niemöller OM, Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, Tonn JC, Atkinson M, Mörtl S, Belka C.

Radiat Oncol. 2011 Nov 10;6:153. doi: 10.1186/1748-717X-6-153.

28.

α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status.

Eigenbrod S, Roeber S, Thon N, Giese A, Krieger A, Grasbon-Frodl E, Egensperger R, Tonn JC, Kreth FW, Kretzschmar HA.

J Neuropathol Exp Neurol. 2011 Nov;70(11):970-8. doi: 10.1097/NEN.0b013e3182333ef5.

PMID:
22002423
29.

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.

Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW.

Cancer. 2012 Jan 15;118(2):452-60. doi: 10.1002/cncr.26298. Epub 2011 Jun 29.

30.

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC; German Glioma Network.

Int J Cancer. 2011 Aug 1;129(3):659-70. doi: 10.1002/ijc.26083.

31.

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.

PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.

32.

Comprehensive neuropathologic analysis of genetic prion disease associated with the E196K mutation in PRNP reveals phenotypic heterogeneity.

Eigenbrod S, Frick P, Giese A, Schelzke G, Zerr I, Kretzschmar HA.

J Neuropathol Exp Neurol. 2011 Mar;70(3):192-200. doi: 10.1097/NEN.0b013e31820cd8a4.

PMID:
21293298
33.

Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.

Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Pöpperl G, Kreth FW.

Neuro Oncol. 2011 Mar;13(3):307-16. doi: 10.1093/neuonc/noq196. Epub 2011 Feb 3.

34.

Genetic prion disease with codon 196 PRNP mutation: clinical and pathological findings.

Schelzke G, Eigenbrod S, Romero C, Varges D, Breithaupt M, Taratuto AL, Kretzschmar HA, Zerr I.

Neurobiol Aging. 2011 Apr;32(4):756.e1-9. doi: 10.1016/j.neurobiolaging.2010.11.023. Epub 2011 Jan 12.

PMID:
21232818
35.

Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.

Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, Popperl G, Belka C, Kretzschmar HA, Tonn JC, Kreth FW.

J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):441-6. doi: 10.1136/jnnp.2010.214593. Epub 2010 Sep 22.

PMID:
20861061
36.

Cerebral angiitis in four patients with chronic GVHD.

Sostak P, Padovan CS, Eigenbrod S, Roeber S, Segerer S, Schankin C, Siegert S, Saam T, Theil D, Kolb HJ, Kretzschmar H, Straube A.

Bone Marrow Transplant. 2010 Jul;45(7):1181-8. doi: 10.1038/bmt.2009.323. Epub 2009 Nov 16.

PMID:
19915632
37.

Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.

Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, Tonn JC, Kretzschmar HA, Kreth FW.

J Neuropathol Exp Neurol. 2009 Nov;68(11):1219-28. doi: 10.1097/NEN.0b013e3181bee1f1.

PMID:
19816195
38.

MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease.

Meissner B, Kallenberg K, Sanchez-Juan P, Ramljak S, Krasnianski A, Heinemann U, Eigenbrod S, Gelpi E, Barsic B, Kretzschmar HA, Schulz-Schaeffer WJ, Knauth M, Zerr I.

J Neurol. 2009 Mar;256(3):355-63. doi: 10.1007/s00415-009-0026-z. Epub 2009 Jan 23.

PMID:
19159063
39.

Evidence for an association of prion protein and sphingolipid-mediated signaling.

Schmalzbauer R, Eigenbrod S, Winoto-Morbach S, Xiang W, Schütze S, Bertsch U, Kretzschmar HA.

J Neurochem. 2008 Aug;106(3):1459-70. doi: 10.1111/j.1471-4159.2008.05498.x. Epub 2008 Jun 28.

40.

Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M, Bertsch U, Kretzschmar H.

J Clin Invest. 2006 Dec;116(12):3204-10.

41.

Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD?

Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M, Ciesielczyk B, Meissner B, Krasnianski A, Bartl M, Heinemann U, Varges D, Eigenbrod S, Kretzschmar HA, Green A, Zerr I.

BMC Neurol. 2006 Sep 21;6:35.

42.

Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells.

Eigenbrod S, Derwand R, Jakl V, Endres S, Eigler A.

Immunol Invest. 2006;35(2):149-65.

PMID:
16698674
43.

[Drug-induced pancreatitis].

Eigler A, Eigenbrod S, Endres S.

Dtsch Med Wochenschr. 2003 Feb 21;128(8):366-9. Review. German. No abstract available.

PMID:
12594621

Supplemental Content

Loading ...
Support Center